Joseph Ciccolini
YOU?
Author Swipe
View article: Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens Open
These findings suggest that optimizing dosing strategies can yield meaningful economic and environmental benefits in ICI therapy while maintaining drug exposure within levels defined by US Food and Drug Administration criteria or broader t…
View article: Translational approach to study pathophysiological mechanisms and find out prognostic factors of immune checkpoint inhibitors-induced myocarditis
Translational approach to study pathophysiological mechanisms and find out prognostic factors of immune checkpoint inhibitors-induced myocarditis Open
Introduction Immune checkpoint inhibitors (ICIs) are widely used in cancer therapy but can trigger severe immune-related adverse events, including myocarditis (ICI-M), a potentially life-threatening condition. While early detection of ICI-…
View article: Combined in vivo and in cellulo approach to study the role of endothelial cells and the NLRP3 inflammasome in cardiac dysfunction associated with immune-mediated myocarditis
Combined in vivo and in cellulo approach to study the role of endothelial cells and the NLRP3 inflammasome in cardiac dysfunction associated with immune-mediated myocarditis Open
Introduction Immunotherapy has led to considerable clinical improvement in cancer patients, but is associated with serious side effects such as myocarditis, which is associated with a high mortality risk. Immune checkpoint inhibitor-induce…
View article: DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study
DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study Open
Background Anticancer drug 5FU is extensively metabolized by dihydropyrimidine dehydrogenase (DPD), an enzyme with high interindividual variability. Poor metabolizer (PM, i.e., DPD deficient) patients are at risk of life‐threatening toxici…
View article: Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing
Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing Open
Background Imatinib is the treatment of elderly or frail patients with chronic myeloid leukemia (CML). Trough levels of around 1000 ng/ml are considered as the target exposure. Objectives We searched for baseline parameters associated with…
View article: Preclinical Pharmacokinetic-Pharmacodynamic Modeling of Antibody Nanoconjugates for Breast Cancer Treatment
Preclinical Pharmacokinetic-Pharmacodynamic Modeling of Antibody Nanoconjugates for Breast Cancer Treatment Open
Over the past five years, the number of antibody–drug conjugates (ADCs) entering the oncology market has surged. By contrast, the clinical use of immunoliposomes—nanoparticles that also employ antibodies as targeting agents (i.e., antibody…
View article: Pharmacokinetic-pharmacodynamic modeling of antibody nanoconjugates in breast cancer treatment
Pharmacokinetic-pharmacodynamic modeling of antibody nanoconjugates in breast cancer treatment Open
While the number of antibody-drug conjugates (ADCs) reaching the oncology market has exploded over the past five years, the clinical use of immunoliposomes, nanoparticles that also carry antibodies as targeting agents (i.e., antibody-nanoc…
View article: E-R relationships with immune checkpoint inhibitors
E-R relationships with immune checkpoint inhibitors Open
International audience
View article: A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution
A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution Open
International audience
View article: Bispecific Antibodies In Multiple Myeloma: Benchmarking & Pharmacological Consideration
Bispecific Antibodies In Multiple Myeloma: Benchmarking & Pharmacological Consideration Open
International audience
View article: Place des anticorps conjugués dans le carcinome urothélial
Place des anticorps conjugués dans le carcinome urothélial Open
International audience
View article: Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning
Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning Open
Aim To evaluate the effectiveness of a Bayesian adaptive dosing strategy in achieving target busulfan exposure in adult patients undergoing haematopoietic cell transplantation (HCT). Methods This study included 71 adult patients scheduled …
View article: Retards d’élimination du MTX: Aspects pharmacométriques
Retards d’élimination du MTX: Aspects pharmacométriques Open
International audience
View article: Antibody Drug Conjugates: when magic bullet does not necessarily mean magic pharmacology
Antibody Drug Conjugates: when magic bullet does not necessarily mean magic pharmacology Open
International audience
View article: PK/PD relationships with immune checkpoint inhibitors: is the earth flat?
PK/PD relationships with immune checkpoint inhibitors: is the earth flat? Open
International audience
View article: Bioanalyse des biothérapies: application au STP en oncologie clinique de routine
Bioanalyse des biothérapies: application au STP en oncologie clinique de routine Open
International audience
View article: Suivi Thérapeutique Pharmacologique des inhibiteurs de point de contrôle de l'immunité: quel niveau de preuve?
Suivi Thérapeutique Pharmacologique des inhibiteurs de point de contrôle de l'immunité: quel niveau de preuve? Open
National audience
View article: CDA deficiency is not associated with higher sensitivity to immune checkpoint inhibitors in melanoma patients
CDA deficiency is not associated with higher sensitivity to immune checkpoint inhibitors in melanoma patients Open
View article: Pharmacometrics as a decision-making tool with immune checkpoint inhibitors: finding the perfect blend?
Pharmacometrics as a decision-making tool with immune checkpoint inhibitors: finding the perfect blend? Open
International audience
View article: 1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial Open
View article: ADC in oncology, reality beyond the myth
ADC in oncology, reality beyond the myth Open
International audience
View article: Modèles mathématiques et médecine de précision en oncologie: individualisation des traitements en pratique clinique de routine
Modèles mathématiques et médecine de précision en oncologie: individualisation des traitements en pratique clinique de routine Open
International audience
View article: Is Biology soluble in Ideology?
Is Biology soluble in Ideology? Open
International audience
View article: Nanoparticules en Oncologie: enjeux & Perspectives
Nanoparticules en Oncologie: enjeux & Perspectives Open
International audience
View article: Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy.
Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy. Open
e18522 Background: Imatinib is a mainstay of treatment for patients with chronic myeloid lymphoma (CML). Exposure-response relationships have been demonstrated and trough levels between 800 and 1000 ng/ml are usually associated with Major …
View article: Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money?
Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money? Open
3085 Background: Immune checkpoint inhibitors are given as fixed doses, which may lead to drug exposure exceeding the plasma concentrations required for target engagement. If confirmed, this could pave the way for de-escalating treatments …
View article: Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II Open
View article: Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I Open
View article: 76P Pegylated immunoliposome encapsulating docetaxel: In vitro activity and optimal pharmacokinetics in a breast cancer model
76P Pegylated immunoliposome encapsulating docetaxel: In vitro activity and optimal pharmacokinetics in a breast cancer model Open
Most cytotoxics used in oncology have a narrow therapeutic index, a high toxicity profile and low specific tissue diffusion to cancer cells, thus calling for the development of new delivery systems. Among these cytotoxic, docetaxel is used…
View article: Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models
Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models Open